Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
MELVILLE, N.Y.--(BUSINESS WIRE)--Feb. 10, 2009-- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals...
Read more about OSI Pharmaceuticals Announces Notification of ANDA Filing for Tarceva
Study is Second Positive Phase III Trial of Tarceva as First-Line Maintenance Therapy MELVILLE, N.Y.--(BUSINESS WIRE)-- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that its U.S....
MELVILLE, N.Y., Nov 26, 2008 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) welcomes today's announcement by the U.K.'s National Institute for Health and Clinical Excellence (NICE)...
First EGFR Targeted and Oral Therapy to Improve Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer Following Initial Treatment SOUTH SAN FRANCISCO, Calif. & MELVILLE,...
Arginine vasopressin (AVP) receptor antagonist now approved in single-use premixed formulation DEERFIELD, Illinois, October 22, 2008 — Astellas Pharma US, Inc. today announced that the U.S. Food...
Follow U.S. news
